It does not penetrate the blood–brain barrier to a significant amount and thus combines an effective block of the H1 receptor in peripheral tissue with a low incidence of central side effects, i.e. seldom causing sedation or drowsiness. It was patented in 1983 by Almirall S.A and came into medical use in 1990.
Comments
Post a Comment